val between each treatment was determined for each patient by the evaluation of the effect of the first course. Muscle strength was evaluated by a computerised analyser. Clinical improvement was seen in 12 patients treated with IVIg (67%). Isometric 
Discussion
Several previous studies have shown the beneficial effect of IVIg in patients with multifocal motor neuropathy over a period of less than 12 months; for example, IVIg was found to be effective in 52 of 60 treated patients (87%).8-18 Our study was designed to assess its efficiency on a large number patients over longer periods. Twelve patients (67%) showed an increase in strength > 30% at the end of the study, with a mean follow up of 25-3 months, the longest period of evaluation being four years. It was possible to differentiate two types of response after the first treatment: in the first group, eight patients improved temporarily and it was necessary to treat them by periodic infusions at intervals based on the findings at the first treatment with a mean interval of 53 days. The other group of four patients improved after the first infusion and continued to improve with intermittent IVIg treatment for several months, allowing treatment to be withdrawn for two of them when recovery was complete, without deterioration after one year. Previous cases of long term remissions are very rare 8 0 II but justify careful evaluation of treatment by repetitive examinations after the first course of IVIg on the one hand, and by trying to reduce the frequency of infusions leading possibly to a withdrawal of IVIg on the other. Improvement was obtained after the first course of IVIg, suggesting that it is necessary to rapidly try other immunosuppressive drugs in patients who fail to improve after the second course of IVIg.
Elliott and Pestronk'9 documented a patient who deteriorated with monthly IVIg infusions for seven months after an initial improvement. This type of evolution seems to be rare. In our study, only one patient (3) out of 12 who initially improved after IVIg further deteriorated. Moreover, the maintenance of the beneficial effect of IVIg long term was documented in two patients over four years.
The long term tolerance to IVIg was confirmed although minor reactions were common. We did not find any transmission of HIV or HCV in our patients, who received large quantities of IVIg over a long period. However, the monitoring of serum aminotransferases and HCV antibodies at least twice a year is recommended.20
When patients do not benefit from IVIg infusions, cyclophosphamide is an alternative as Feldman et a17 reported a progressive improvement in all patients they treated. We have treated only three patients with intravenous cyclophosphamide and two with oral therapy. Only one patient improved with cyclophosphamide after failure of IVIg treatment, but the dose was lower than those used by Feldman et al. 7 Hence, if a consensus is realised about the choice of IVIg as a first line treatment, the indication of intravenous cyclophosphamide if IVIg is not effective has yet to be proved by a controlled trial on larger groups of patients. Another indication for cyclophosphamide was proposed by NobileOrazio et all' who reduced the frequency of IVIg infusions by the addition of low doses (1-2 mg/kg/day) of the cytotoxic agent in two patients. We obtained the same result in one of two patients.
As in most studies,'"-'3 it was not possible to document significant changes of anti-GM1 concentrations on long term IVIg therapy, although this was obtained with cyclophosphamide in two patients, who nevertheless did not clinically improve. However, a correlation between the initial presence of high titres of IgM anti-GMI antibodies without IgG and the long lasting response to IVIg was present. This correlation has not been reported by others,18 and further studies are needed to confirm the clinical value of IgG and IgM anti GM1 determination as a factor predictive of response to IVIg. Wepfer showed that apoplexy is due to cerebral haemorrhage. In Historiae apoplecticorum, published in 1658,' is a detailed description of four cases, his first having been studied in 1655. The account of one such case and a brief history of Wepfer is reproduced elsewhere.' This classic text also contains a section: The history of the sickness of Marcello Malpighi, the Pope's physician; with an account of the dissection of his corps.
Malpighi (1628-94) was professor of anatomy at Bologna, Pisa, and Messina. His work formed the basis for the studies of histology, providing accurate descriptions of the lungs, kidneys, spleen, skin, and liver. He first described the capillaries and the layer of the skin, and demonstrated the lymphatic follicles in the spleen, both of which bear his name. Much of modem embryology can be said to be grounded in his examinations of the chick embryo. Biologists owe Malpighi a debt for his early studies on the anatomy of the silkworm.
He achieved considerable eminence and repute, and was appointed physician to Pope Innocent XII.
Wepfer relates the distinguished anatomist's past history of palpitations, stones in the kidneys and bladder, and gout. *This word is not to be found in the OED; I presume it is derived from L caput (head) and plenium (a fullness), hence full-headedness.
